Design Therapeutics Inc (NAS:DSGN)

Q1 2026 Design Therapeutics Inc Earnings Call Transcript

Apr 28, 2026 / 08:30 PM GMT

Release Date Price: $12.81

Transcript 10-Q8-K

Key Points

Positve

The RESTORE-FA trial is proceeding well, with data expected in the second half of 2026.
DT216 has shown promising results in increasing frataxin mRNA and protein levels in cellular models.
The trial design includes multiple biomarker endpoints to evaluate the effectiveness of DT216.
The company is exploring both blood and muscle biomarkers to establish a robust regulatory alignment.
The RESTORE-FA study aims to provide a go/no-go decision, establish clinical proof of concept, and inform regulatory pathways.

Negative

The trial is still in early stages, and no clinical benefit is expected to be observed at this stage.
There is limited information available on muscle RNA or protein in the literature, which may affect biomarker selection.
Assay variability and lack of normalized standards in the FA field pose challenges in evaluating frataxin responses.
The definitive amount of frataxin increase needed for therapeutic effect is still unknown.
The company acknowledges that actual results may differ materially due to various risks and uncertainties.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

DSGN.OQ - Design Therapeutics Inc
Q1 2026 Design Therapeutics Inc Earnings Call
Apr 28, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
I'm Pratik Shah, CEO of Design Therapeutics.

During this presentation, we will use forward-looking statements with regards to our business, R&D activities, and financial conditions, which are subject to known and unknown risks and uncertainties. Actual results may differ materially due to various important factors, including those described in the risk factor section. Of our most recent Form 10-Q filed with the SEC.

Given the nature of the interest in the FA program and the design of the RESTORE-FA trial, we're delighted to provide a general update on our FA program, the key objectives of the RESTORE-FA study, and the multiple biomarker endpoints being evaluated.

We're using this quarter's update

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.